The abstract is read at the publisher; the summary is JClub's.
Perioperative ADT plus apalutamide improved metastasis-free survival and increased pathological complete response or minimal residual disease rates versus ADT plus placebo in 5-year follow-up.
- Why it matters: Relapse after radical prostatectomy remains common in high-risk localized or locally advanced prostate cancer, with up to 50% relapsing within 5 years.
- What they did: In a phase 3 double-blind trial, 2109 newly diagnosed patients received 6 cycles of perioperative ADT plus apalutamide 240 mg/day or ADT plus placebo, then underwent radical prostatectomy with pelvic lymph-node dissection.
- The result: Pathological complete response or minimal residual disease was 8.9% vs 1.0% (odds ratio 10.17; P<0.001), and 5-year metastasis-free survival was 78.2% vs 73.5% (hazard ratio 0.80; P=0.02), with more grade 3–4 adverse events (39.6% vs 31.0%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.